Skip to main content
Premium Trial:

Request an Annual Quote

Bradley Cole

Castle Biosciences announced Bradley Cole has been appointed to its board. Cole is the CFO of Genomic Health and has more than 30 years of experience in finance and operations in the diagnostics and life sciences industries. He also has served as COO of Genomic Health. Prior to joining the firm, he was VP of finance and business development for the endovascular solutions group at Guiidant, and was VP and GM of vascular surgery business unit of Guidant. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.